Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/6/2017
SIETES contiene 91846 citas

 
 
<< anterior 21 a 40 de 4610 siguiente >>
Presentar resultados
Seleccionar todas
23. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
24. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
25. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
26. Cita con resumen
27.Enlace a cita original Cita con resumen
Ariz MJ, Elizondo G. Nuevos antidiabéticos. ¿Qué lugar deben ocupar en terapéutica?. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-8. [Ref.ID 101436]
30.Tiene citas relacionadas Cita con resumen
Wong J, Motulski A, Abrahamowicz M, McGill J, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017;356:j603. [Ref.ID 101417]
31.Tiene citas relacionadas Cita con resumen
Morales DR, Guthrie B. Off-label prescribing of antidepressants. BMJ 2017;356:j849. [Ref.ID 101416]
32. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
33. Cita con resumen
Chen HK, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, Hystad P, Martin RV, Murray BJ, Jessiman B, Wilton AS, Kopp A, Burnett RT. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet 2017;389:718-26. [Ref.ID 101409]
34. Cita con resumen
Machado GC, Maher CG, Herreira PH, Day RO, Pinheiro MB, Ferreira ML. Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Ann Rheum Dis 2017:2 de febrero. [Ref.ID 101391]
35. Cita con resumen
36. Cita con resumen
Jensen AK, Simonsen J, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis. A nationwide registry-based case-control study. Clin Infect Dis 2017:1. [Ref.ID 101381]
37. Cita con resumen
Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation: Cardiovascular Quality and Outcomes 2017;10:e003153. [Ref.ID 101377]
38. Cita con resumen
Saiz Fernández LC. Ensayo EMPA-REG OUTCOME (empagliflozina) El poder de la verdad, la verdad del poder.. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-13. [Ref.ID 101347]
39. Cita con resumen
Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, Currow DC. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med 2017;177:34-42. [Ref.ID 101343]
40. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
Seleccionar todas
 
<< anterior 21 a 40 de 4610 siguiente >>